DUBLIN--(BUSINESS WIRE)--Research and Markets(http://www.researchandmarkets.com/research/6d6bdf/emerging_market_fo) has announced the addition of the "Emerging Market for Clinical Trials in Brazil - Improved Guidelines from ANVISA and CONEP are Shortening the Regulatory Approval Process and Advancing the Market" report to their offering.
Emerging Market for Clinical Trials in Brazil - Improved Guidelines from ANVISA and CONEP are Shortening the Regulatory Approval Process and Advancing the Market that provides key data, information and analysis of the major trends and issues affecting the clinical trial market in Brazil. The report provides comprehensive insight on the reasons for outsourcing clinical trials to Brazil and the key services provided by the Clinical Research Organizations (CROs) of Brazil. The report provides a detailed analysis of the Brazilian market in terms of its size, and the major service offerings of the CROs in Brazil. The report also discusses the factors that are driving the clinical trial market in Brazil. The report delves into the key documents required by the investigator and the sponsor before, during and after the conduct of clinical trials. The report also provides key alliances between the CROs of other countries and the local CROs of Brazil. The report also looks into the major challenges that can restrict the growth of the clinical trials market in Brazil.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by a team of industry experts.
Rising Financial and Regulatory Pressures on Western Pharmaceutical Companies Will Continue to Drive the Clinical Trial Market Growth in Brazil
The pharmaceutical industries of the US and Europe have been facing severe financial constraints over the past few years, which are expected to worsen in the coming years. With constraints such as the increasing cost of introducing New Molecular Entities (NME), which is expected to reach more than $3 billion in 2008, tightening regulatory pressures resulting in fewer FDA and other regulatory agency approvals, blockbuster drugs worth more than $100 billion experiencing patent expiry by 2014, and the drying developmental pipelines of the pharmaceutical industry, cost cutting pressures are mounting on pharmaceutical companies, especially the big ones. These pressures are expected to drive these companies towards low-cost countries such as Brazil for their R&D activities, which are one of their major expenses. Brazil, over the last decade, has developed significant capabilities in clinical trials. Brazil is able to provide significant cost savings in the range of 20-30% for clinical trials. With discovery research occupying close to one-third of the Research and Development (R&D) expenditure for the Western pharmaceutical industry, outsourcing to low-cost countries is logical. As the financial and regulatory pressures grow on the US and European pharmaceutical industry, it is expected to further propel the growth in the clinical trial market in Brazil.
The report analyses the clinical trial market in Brazil, along with the major forces driving the current market and the potential challenges that could restrain the growth. The scope of the report includes:
- Trends in clinical trial registration in Brazil and a comparative analysis of clinical trial registration in Brazil, Russia, India and China (BRIC) and six major Latin American countries.
- Analysis of the key drivers that are fueling the growth of the clinical trial market in Brazil.
- Analysis of the key infrastructural facilities, clinical research professionals and principal investigators in Brazil.
- Analysis of key government regulations in Brazil affecting the clinical trial market.
- Study of 13 major CROs operating in Brazil with SWOT analysis of large multinational CROs.
For more information visit http://www.researchandmarkets.com/research/6d6bdf/emerging_market_fo